دورية أكاديمية
أعرض في EDS

Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.

التفاصيل البيبلوغرافية
العنوان: Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
المؤلفون: Stifter E; Department of Ophthalmology, Medical University of Vienna, Austria., Michels S, Prager F, Georgopoulos M, Polak K, Hirn C, Schmidt-Erfurth U
المصدر: American journal of ophthalmology [Am J Ophthalmol] 2007 Dec; Vol. 144 (6), pp. 886-892. Date of Electronic Publication: 2007 Oct 04.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Country of Publication: United States NLM ID: 0370500 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0002-9394 (Print) Linking ISSN: 00029394 NLM ISO Abbreviation: Am J Ophthalmol Subsets: MEDLINE
أسماء مطبوعة: Publication: 1999- : New York, NY : Elsevier Science
Original Publication: [Chicago, etc., Ophthalmic Pub. Co., etc.]
مواضيع طبية MeSH: Angiogenesis Inhibitors/*therapeutic use , Antibodies, Monoclonal/*therapeutic use , Choroidal Neovascularization/*drug therapy , Macular Degeneration/*drug therapy , Retinal Hemorrhage/*drug therapy, Aged ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Choroidal Neovascularization/etiology ; Female ; Follow-Up Studies ; Humans ; Injections ; Macular Degeneration/complications ; Male ; Retina/pathology ; Retinal Hemorrhage/etiology ; Retrospective Studies ; Tomography, Optical Coherence ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity/physiology ; Vitreous Body
مستخلص: Purpose: To evaluate functional and anatomic effects of intravitreal bevacizumab (Avastin; Roche Pharma, Vienna, Austria) in patients with neovascular age-related macular degeneration (AMD) with large submacular hemorrhages.
Design: Retrospective, clinical study.
Methods: Twenty-one eyes of 19 AMD patients with choroidal neovascularization and large submacular hemorrhage involving the fovea comprising more than 50% of the total lesion area were evaluated. All patients completed at least four months of follow-up; 12 patients fulfilled 12 months or more of follow-up. Patients were treated with up to six intravitreal bevacizumab injections (1 mg/0.04 ml) at a minimum of four-week intervals. Changes from baseline visual acuity (VA) scores, retinal measurements by optical coherence tomography (OCT), angiographic lesion characteristics, and hemorrhage size were analyzed. A safety assessment was performed at all visits.
Results: Intravitreal bevacizumab injections were well tolerated in all patients. At month 4, VA was stable or improved (visual loss of 3 acuity lines or fewer) in 100% and improved by at least 3 lines in 9.5%. Comparable results were found at month 12. On average, the central foveal thickness decreased significantly by 55 microm four weeks after the first injection (P < .001) and by 52 microm at month 4 (P = .002). A significant anatomic improvement also was found for maximum retinal thickness, minimum retinal thickness, and foveal volume (P < .05) and was maintained during four months of follow-up. Mean size of hemorrhage was significantly reduced from 19.7 mm(2) at baseline to 2.5 mm(2) at the four-month follow-up (P < .001).
Conclusions: Intravitreal bevacizumab seems to be a promising therapeutic option in eyes with neovascular AMD and large submacular hemorrhages, with a stabilization in VA and anatomic improvement.
المشرفين على المادة: 0 (Angiogenesis Inhibitors)
0 (Antibodies, Monoclonal)
0 (Antibodies, Monoclonal, Humanized)
0 (VEGFA protein, human)
0 (Vascular Endothelial Growth Factor A)
2S9ZZM9Q9V (Bevacizumab)
تواريخ الأحداث: Date Created: 20071006 Date Completed: 20080129 Latest Revision: 20220311
رمز التحديث: 20240628
DOI: 10.1016/j.ajo.2007.07.034
PMID: 17916314
قاعدة البيانات: MEDLINE
الوصف
تدمد:0002-9394
DOI:10.1016/j.ajo.2007.07.034